nach oben

Drugs

Erschienen in:

01.04.2013 | Leading Article

Multifocal Motor Neuropathy: Current Therapies and Novel Strategies

verfasst von: Eduardo Nobile-Orazio, Francesca Gallia

Erschienen in: Drugs | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Multifocal motor neuropathy (MMN) is a purely motor mononeuritis multiplex characterized by the presence of conduction block on motor but not on sensory nerves and by the presence of high titers of anti-GM1 antibodies. Several data point to a pathogenetic role of the immune system in this neuropathy, although this has not yet been proved. Several uncontrolled studies and randomized controlled trials have demonstrated the efficacy of therapy with high-dose intravenous immunoglobulin (IVIg) in MMN. However, this therapy has a short-lasting effect that needs to be maintained with periodic infusions. This can be partly overcome by the use of subcutaneous immunoglobulin (SCIg) at the same dose. The high cost and need for repeated infusions have led to the search for other immune therapies, the efficacy of which have not yet been confirmed in randomized trials. In addition, some therapies, including corticosteroids and plasma exchange, are not only ineffective but have been associated with clinical worsening. More recently, a number of novel therapies have been investigated in MMN, including interferon-β1a, the anti-CD20 monoclonal antibody rituximab and the complement inhibitor eculizumab. Preliminary data from open-label uncontrolled studies show that some patients improve after these therapies; however, randomized controlled trials are needed to confirm efficacy. Until then, IVIg (and SCIg) remains the mainstay of treatment in MMN, and the use of other immune therapies should only be considered for patients not responding to, or becoming resistant to, IVIg.

Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663–80.PubMedCrossRef

Vlam L, van der Pol W-L, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48–58.PubMedCrossRef

Roth G, Rohr J, Magistris MR, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Eur Neurol. 1986;25:416–23.PubMedCrossRef

Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology. 1986;36:1260–3.PubMedCrossRef

Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 1988;11:103–7.PubMedCrossRef

Pestronk A, Cornblath DR, Ilyas A, et al. A treatable multi-focal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.PubMedCrossRef

van Schaik IN, Van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;2:CD004429.PubMed

Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75:818–25.PubMedCrossRef

Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 1001;115:4–18.CrossRef

10.

Van den Berg-Vos RM, Franssen H, Wokke JHJ, et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin. Neurology. 2000;48:919–26.

11.

Nobile-Orazio E, Gallia F, Terenghi F, et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266:156–63.PubMedCrossRef

12.

Gooch CL, Amato AA. Are anti-ganglioside antibodies of clinical value in multifocal motor neuropathy? Neurology. 2010;75:1950–1.PubMedCrossRef

13.

van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta analysis. Neurology. 1995;45:1570–7.PubMedCrossRef

14.

Bech E, Andersen H, Orntoft TF, Jakobsen J. Association of IgM type anti-GM1 antibodies and muscle strength in chronic acquired demyelinating polyneuropathy. Ann Neurol. 1998;43:72–8.PubMedCrossRef

15.

Taylor BV, Gross LA, Windebank AJ. The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 1996;47:951–5.PubMedCrossRef

16.

Arunachalam R, Osei-Lah A, Mills KR. Transcutaneous cervical root stimulation in the diagnosis of multifocal motor neuropathy with conduction block. J Neurol Neurosurg Psychiatry. 2003;74:1329–31.PubMedCrossRef

17.

Akaza M, Kanouchi T, Inaba A, et al. Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. 2011;43:274–82.PubMedCrossRef

18.

Deroide N, Uzenot D, Verscheuren A, et al. Triple-stimulation technique in multifocal motor neuropathy with conduction block. Muscle Nerve. 2007;35:632–6.PubMedCrossRef

19.

Nodera H, Bostock H, Yzumi Y, et al. Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology. 2006;67:280–7.PubMedCrossRef

20.

Olney RK, Lewis RA, Putnam TD, Campellone JV. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003;27:117–21.PubMedCrossRef

21.

Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society. First revision. J Peripher Nerv Syst. 2010;15:295–301.CrossRef

22.

Santoro M, Uncini A, Corbo M, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol. 1992;31:385–90.PubMedCrossRef

23.

Uncini A, Santoro M, Corbo M, et al. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve. 1993;16:610–5.PubMedCrossRef

24.

Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to anti-ganglioside sera. Muscle Nerve. 1993;16:587–93.PubMedCrossRef

25.

Paparounas K, O’Hanlon GM, O’Leary CP, et al. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain. 1999;122:807–16.PubMedCrossRef

26.

Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol. 1995;38:111–8.PubMedCrossRef

27.

Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992;42:506–9.PubMedCrossRef

28.

Charles N, Benoit P, Vial C, et al. Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet. 1992;340:182.PubMedCrossRef

29.

Nobile-Orazio E, Meucci N, Barbieri S, et al. High dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993;43:537–44.PubMedCrossRef

30.

Kermode AG, Laing BA, Carroll WM, Mastaglia FL. Intravenous immunoglobulin for multifocal motor neuropathy. Lancet. 1992;340:920–1.PubMedCrossRef

31.

Chaudhry V, Corse A, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33:237–42.PubMedCrossRef

32.

Azulay J-P, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology. 1994;44:429–32.PubMedCrossRef

33.

Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248–52.PubMedCrossRef

34.

Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 2000;55:1257–62.CrossRef

35.

Léger J-M, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain. 2001;124:145–53.PubMedCrossRef

36.

Hahn AF, Beydoun SR, Lawson V, The IVIg in MMN Study Team, et al. A phase III randomized, placebo-controlled study of the efficacy and safety of 10 % liquid intravenous immunoglobulin (IVIg) for the treatment of multifocal motor neuropathy (abstract). J Peripher Nerv Syst. 2012;17:243–4.

37.

Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002;125:1875–86.PubMedCrossRef

38.

Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology. 2004;62:666–8.PubMedCrossRef

39.

Léger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry. 2008;79:93–6.PubMedCrossRef

40.

Bauman A, Hess CW, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol. 2009;256:608–14.CrossRef

41.

Van Asseldonk JTH, Van den Berg LH, Kalmijn S, et al. Axonal loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:743–7.PubMedCrossRef

42.

Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264–9.PubMedCrossRef

43.

Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93–100.PubMedCrossRef

44.

Harbo T, Andersen H, Jacobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology. 2010;75:1377–80.PubMedCrossRef

45.

Misbah SA, Baumann A, Fazio R, et al. A smooth transition protocol going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst. 2011;16:92–7.PubMedCrossRef

46.

Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single-blinded cross-over trial. Eur J Neurol. 2009;16:631–8.PubMedCrossRef

47.

Cocito D, Serra G, Paolasso I, et al. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. J Peripher Nerv Sys. 2012;17:426–8.CrossRef

48.

Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibodies and intravenous immunoglobulin for rheumatic diseases: rationale and mechanism of action. Nature Clin Pract Rheumatol. 2007;3:262–72.CrossRef

49.

Van den Berg LH, Franssen H, Wokke JHJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain. 1998;121:421–8.PubMedCrossRef

50.

Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous γ-globulin inhibits binding of anti-GM1 on its target antigen. Ann Neurol. 1996;1996(39):136–9.CrossRef

51.

Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM mediated complement deposition in MMN. J Neuroimmunol. 2010;229:256–62.PubMedCrossRef

52.

Yuki N, Watanabe H, Nakajima T, Späeth PJ. IVIg blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2011;82:87–91.PubMedCrossRef

53.

Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778–83.PubMedCrossRef

54.

Lehman HC, Hoffmann FR, Fusshoeller A, et al. The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci. 2008;271:34–9.CrossRef

55.

Carpo M, Cappellari A, Mora G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology. 1998;50:1480–2.PubMedCrossRef

56.

Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Sys. 2010;15:1–9.CrossRef

57.

Umapathi T, Hughes R, Nobile-Orazio E, Leger J. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2012;4:CD003217.PubMed

58.

Nobile-Orazio E, Gallia F, Tuccillo F, Terenghi F. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr Opin Neurol. 2010;23:519–23.PubMedCrossRef

59.

Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991;30:397–401.PubMedCrossRef

60.

Krarup C, Stewart JD, Sumner AJ, et al. A syndrome of asymmetric limb weakness with motor conduction block. Neurology. 1990;40:118–27.PubMedCrossRef

61.

Pringle CE, Belden J, Veitch JE, Brown WF. Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle Nerve. 1997;20:347–51.PubMedCrossRef

62.

Axelson HW, Oberg G, Ashmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand. 2008;117:432–4.PubMedCrossRef

63.

Meucci N, Cappellari A, Barbieri S, et al. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997;63:765–9.PubMedCrossRef

64.

Bouche P, Moulonguet A, Younes-Chennoufi AB, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 1995;59:38–44.PubMedCrossRef

65.

Hausmanowa-Petrusewicz I, Rowisnka-Marcinska K, Kopec K. Chronic acquired demyelinating motor neuropathy. Acta Neurol Scand. 1991;84:40–5.PubMedCrossRef

66.

Nemni R, Santuccio G, Calabrese E, Galardi G, Canal N. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol. 2003;250:1118–20.PubMedCrossRef

67.

Nobile-Orazio E, Terenghi F, Cocito D, et al. Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst. 2009;14:203–5.PubMedCrossRef

68.

Benedetti L, Grandis M, Nobbio L, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve. 2004;29:748–9.PubMedCrossRef

69.

Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–10.PubMedCrossRef

70.

Sanford M, Lyseng-Williamson KA. Subcutaneous recombinant interferon-β-1a (Rebif^®): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011;71(14):1865–91.PubMedCrossRef

71.

Weinstock-Guttman B, Ransohoff RM, Kinkel P, et al. The interferon: biological effects, mechanism of action and use in multiple sclerosis. Ann Neurol. 1995;37:7–15.PubMedCrossRef

72.

Martina ISJ, van Doorn PA, Schmitz PIM, et al. Chronic motor neuropathies: response to interferon-β1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry. 1999;66:197–201.PubMedCrossRef

73.

Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon-β1A. Neurology. 2000;54:1518–21.PubMedCrossRef

74.

Radziwill AJ, Botez S, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. J Peripher Nerv Syst. 2009;14:201–2.PubMedCrossRef

75.

Dalakas MC. Inhibition of B cell functions: implications for neurology. Neurology. 2008;70:2252–60.PubMedCrossRef

76.

Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445–76.PubMedCrossRef

77.

Benedetti L, Briani C, Fazio R, et al. Rituximab in patients with CIDP: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82:306–8.PubMedCrossRef

78.

Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286–93.PubMedCrossRef

79.

Pestronk A, Florence J, Miller T, et al. Treatment of IgM associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485–9.PubMedCrossRef

80.

Rojas-Garcia R, Gallardo E, de Andrés I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology. 2003;61:1814–6.PubMedCrossRef

81.

Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178–9.PubMedCrossRef

82.

Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35:66–9.PubMedCrossRef

83.

Stielgbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromusc Disord. 2009;19:473–5.CrossRef

84.

Chaudhry V, Cornblath DR. An open label trial of rituximab (Rituxan^®) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196–201.PubMedCrossRef

85.

Michaud A, Delmont E, Jeandel PY, Desnuelle C. Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term ritxumab (in French). Rev Neurol (Paris). 2011;167:916–20.CrossRef

86.

Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the research on adverse drug event and reports project. Blood. 2009;113:4834–40.PubMedCrossRef

87.

Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–64.PubMedCrossRef

88.

Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;12:1233–43.CrossRef

89.

Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84–91.PubMedCrossRef

90.

Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Mol Immunol. 2009;47:185–95.PubMedCrossRef

91.

Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain–Barré syndrome. J Neuroimmunol. 2008;205:101–4.PubMedCrossRef

92.

Schweighofer CD, Wendtner C-M. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther. 2010;3:53–67.PubMedCrossRef

93.

Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786–801.PubMedCrossRef

94.

Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257:913–9.PubMedCrossRef

95.

Avivi I, Chakrabarti S, Kottaridis P, et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transpl. 2004;34:137–42.CrossRef

96.

Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25:673–98.PubMedCrossRef

97.

Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion and memory. J Immunol. 2000;164:5761–70.PubMed

98.

Zhang Z, Zhang Z-Y, Fauser U, et al. FTY720 ameliorates experimental autoimmmune neuritis by inhibition of lymphocytes and monocytes infiltration in peripheral nerves. Exp Neurol. 2008;210:681–90.PubMedCrossRef

Titel: Multifocal Motor Neuropathy: Current Therapies and Novel Strategies
verfasst von: Eduardo Nobile-Orazio
Francesca Gallia
Publikationsdatum: 01.04.2013
Verlag: Springer International Publishing AG
Erschienen in: Drugs / Ausgabe 5/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0029-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Clinical Strategies to Enhance the Efficacy of Nicotine Replacement Therapy for Smoking Cessation: A Review of the Literature

Lorcaserin: A Review of its Use in Chronic Weight Management

Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions

Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin?

Optimal Management of Metastatic Renal Cell Carcinoma: Current Status

Mipomersen Sodium: First Global Approval